The Role of Exercise in Management of Patients with Heart Failure

Similar documents
Cardiac Rehabilitation for Heart Failure Patients. Jia Shen MD, MPH Assistant Professor of Medicine UC San Diego Health System

DISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE

WHAT IS ADVANCED HEART FAILURE? James C. Fang, MD, FACC Professor and Chief Cardiovascular Division University of Utah School of Medicine

A patient with heart failure and resynchronisation/ about training and exercise?

Devices and Other Non- Pharmacologic Therapy in CHF. Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine

The Role of Cardiac Rehabilitation. The Role of Cardiac Rehabilitation. in Heart Failure. in Heart Failure. History of Cardiac Rehab.

Bi-Ventricular pacing after the most recent studies

Therapeutic Targets and Interventions

HEART FAILURE AN OMINOUS DISEASE

Congestive Heart Failure: Outpatient Management

The ACC Heart Failure Guidelines

Heart Failure with Preserved EF (HFPEF) Epidemiology and management

علم االنسان ما لم يعلم

Patient-Reported Outcomes: A Critical Insight into the Impact of Therapy

Management Strategies for Advanced Heart Failure

All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, MFMER

The role of remote monitoring in preventing readmissions after acute heart failure

Heart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist

Cardiac Resynchronization Therapy Guidelines and Missing Groups

2016 Update to Heart Failure Clinical Practice Guidelines

Heart Failure Challenges and Unmet needs

Value of Cardiac Rehabilitation for Improving Patient Outcomes

Updates in Congestive Heart Failure

Heart Failure Guidelines For your Daily Practice

Heart Failure Update. Bibiana Cujec MD May 2015

Supplementary Online Content

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure

Gerasimos Filippatos MD, FESC, FCCP, FACC

Disclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17

Atrial Fibrillation and Heart Failure

New Agents for Heart Failure: Ivabradine Jeffrey S. Borer, MD

I have no disclosures. Disclosures

Evidence of Baroreflex Activation Therapy s Mechanism of Action

HFpEF. April 26, 2018

Take-home Messages from Recent Heart Failure Trials: Heart Rate as a Target

Rebuilding and Reinvigorating Cardiac Rehabilitation in 2018

Comparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart failure

PHYSICAL AND SEXUAL ACTIVITIES

Heart Failure Overview. Dr Chris K Y Wong

Biological Correlates of Frailty in Older Heart Failure Patients

Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy

Interventional solutions for atrial fibrillation in patients with heart failure

Heart Failure with Reduced EF. Dino Recchia, MD, FACC, FHFSA

Large RCT s of CRT 2002 to present

Device Interrogation- Pacemakers, ICD and Loop Recorders. Dulce Obias-Manno, RN, MHSA, CCDS,CEPS, FHRS Device Clinic Coordinator, MHVI

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Heart Failure Update John Coyle, M.D.

Dipartimento di Scienze Cardiovascolari Università Campus Bio-Medico di Roma Dott. Vito Calabrese

Value of cardiac rehabilitation Prof. Dr. L Vanhees

His Bundle Pacing in Bundle Branch Block May 11, 2017

Cardiovascular Guideline-Driven Pharmacotherapies: Optimizing Management

HFpEF: How to optimise management

HFpEF: Pathophysiology & Treatment

Gender and cardiac resynchronization therapy. Chairs: David Heaven & Belinda Green. Gender and Cardiac Resynchronisation Therapy

Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure

Nitrate s Effect on Activity Tolerance in Heart Failure with Preserved Ejection Fraction (NEAT) A Randomized Clinical Trial

Chronic Primary Mitral Regurgitation

Early Recognition & Management of Heart Failure in the Elderly

How might biomarkers and other strategies help establish adequacy of care?

Heart Failure. GP Update Refresher 18 th January 2018

The Counter HF Clinical Study for Heart Failure

From PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group

Managing Atrial Fibrillation in the Heart Failure Patient

ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

Summary, conclusions and future perspectives

WHAT S NEW IN HEART FAILURE

Heart Failure Therapies State of the Art 2017

Need to Know: Implantable Devices. Carolyn Brown RN, MN, CCRN Education Coordinator Emory Healthcare Atlanta, Georgia

This is What I do to Improve CRT Response for CRT Non-Responders

CRT Vs RV Pacing Benefits

State-of-the-Art Management of Chronic Systolic Heart Failure

Cardiac Rehabilitation Program for LVAD Patients. Dr Katherine Fan Consultant Cardiologist Grantham Hospital, Hong Kong SAR

Μαρία Μπόνου Διευθύντρια ΕΣΥ, ΓΝΑ Λαϊκό

How atrial fibrillation should be treated in the heart failure patient?

New Advances in the Diagnosis and Management of Acute and Chronic Heart Failure

ESC Guidelines. ESC Guidelines Update For internal training purpose. European Heart Journal, doi: /eurheart/ehn309

Innovation therapy in Heart Failure

Biomarker-guided HF: What have we learned (so far)?

Heart Failure Medical and Surgical Treatment

SCOMPENSO CARDIACO: IL PUNTO DELLA RICERCA

Disclosures. Preventing Heart Failure Re-admissions in Deaths Due to Cardiovascular Disease (United States: ) Heart Failure

Disclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017

Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA

Checklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute

Rehabilitation for Cardiovascular Disease: Updates and Opportunities. Jonathan R. Murrow, MD Associate Professor of Medicine (Cardiology)

Εφαρμογή των νεώτερων κατευθυντήριων οδηγιών στην καρδιακή ανεπάρκεια σε αρρώστους με αμυλοείδωση

Surgery and device intervention for the elderly with heart failure: assessing the need. Devices and Technology for heart failure in 2011

Exercise Prescription for Patients with CHF

BSH Annual Autumn Meeting 2017

What s new in 2016 Guidelines of the European Society of Cardiology? HEART FAILURE. Marc Ferrini (Lyon Fr)

HEART FAILURE: PHARMACOTHERAPY UPDATE

Heart Failure. Guillaume Jondeau Hôpital Bichat, Paris, France

THE PROPER APPROACH TO DIAGNOSING HEART FAILURE WITH PRESERVED EJECTION FRACTION

Outline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan

HEART FAILURE IN WOMEN. Marian Limacher, MD Division of Cardiovascular Medicine University of Florida

What s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine

Heart Rhythm Congress 2016 Chronotropic incompetence in heart failure patients

Diagnosis and management of Chronic Heart Failure in 2018: What does NICE say? PCCS Meeting Issues and Answers Conference Nottingham

Case (Coding Nightmare) Current Dilemmas in Heart Failure : Closing the Gap between Clinical Care and Coding. Current Dilemmas in Heart Failure :

Heart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre

Transcription:

The Role of Exercise in Management of Patients with Heart Failure Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA Chair, ACC Prevention of Cardiovascular Disease Leadership Council and Section Director, Seinsheimer Cardiovascular Health Program Co-Director, Women s Heart Care Medical University of South Carolina

Disclosures Advisory boards Amgen AstraZeneca Sanofi Regeneron

Heart failure and exercise tolerance Variety of non-specific symptoms Most frequent: exertional breathlessness Fatigue, lethargy, edema Taylor RS, et al. Cochrane Database of Systematic Reviews. 2014;doi:10.1002/14651858.CD003331.pub4 European Heart Journal doi:10.1093/eurheartj/ehw128

Heart failure and exercise tolerance Marked reductions in exercise capacity Detrimental effects on activities of daily living Health-related quality of life Hospital admission rate Mortality Taylor RS, et al. Cochrane Database of Systematic Reviews. 2014;doi:10.1002/14651858.CD003331.pub4

What is the evidence for benefit of exercise in HF?

Cardiac rehabilitation in HF Definition The coordinated sum of activities required to influence favorably the underlying cause of CVD, as well as to provide the best possible physical, mental, and social conditions, so that the patients may, by their own efforts, preserve or resume optimal functioning in their community and through improved health behavior, slow or reverse progression of disease. A central component of CR is exercise training. BACPR, 2015

Role of Exercise: What is the evidence? HFrEF, HFpEF Older adults Cardiac resynchronization therapy Left ventricular assist device

HF-ACTION Trial Assessed safety and efficacy of ET for medically stable patients with HFrEF (LVEF <35%, NYHA class II to IV) Large and diverse population (n=2331) RCT design Optimal medical management including ACEI and BB 40% had ICDs and 18% had biventricular pacing JAMA. 2009;301:1439-50

HF-ACTION Trial Exercise group Began with 36 supervised training sessions for 30 minutes of exercise 3 days/week Individualized exercise prescription based on CPX At halfway point, received home treadmill or stationary bicycle and heart-rate monitor Instructed to exercise 5 times per week at moderate intensity for 40 minutes Usual-care group Given instructions regarding benefits of exercise at moderate intensity for 30 minutes daily JAMA. 2009;301:1439-50

HF-ACTION Trial Primary composite endpoint All-cause mortality or all-cause hospital stay After median f/u 30 months Non-significant reduction primary combined endpoint HR 0.93, 95% CI: 0.84 to 1.02; p=0.13 After adjustment for baseline characteristics predictive of clinical outcomes Duration CPX, LVEF, hx afib, depression HR 0.89, 95% CI: 0.81 to 0.99; p=003 Secondary endpoint CV mortality or HF hospitalization HR 0.85, 95% CI: 0.74 to 0.99; p=0.03 JAMA. 2009;301:1439-50

Efficacy and Safety of Exercise Training in Patients With Chronic Heart Failure: HF-ACTION Randomized Controlled Trial CI indicates confidence interval; HR, hazard ratio. a Adjusted for key prognostic factors. JAMA. 2009;301(14):1439-1450. doi:10.1001/jama.2009.454

Efficacy and Safety of Exercise Training in Patients With Chronic Heart Failure: HF-ACTION Randomized Controlled Trial CI indicates confidence interval; HR, hazard ratio. a Adjusted for key prognostic factors. JAMA. 2009;301(14):1439-1450. doi:10.1001/jama.2009.454

HF-ACTION Trial Subsequent analysis demonstrated that patients who achieved increased exercise volume during the trial had relatively better outcomes Concept of dose-response relationship Exercise volume was significant (p=0.001) predictor of reduced mortality (all-cause and cardiac) or hospitalization (all-cause or HF) JAMA. 2009;301:1439-50 JACC. 2012;60:1899-905

HF-ACTION Trial Criticisms of HF-ACTION Significant benefits after adjustment for predictive factors of the same outcomes Need to extend number of sites to achieve enrollment goals ET is inherently problematic Adherence to prescribed exercise volume was limited Only 30% exercised at or above target Still leaves residual concerns and questions due to limited enrollment and suboptimal adherence JAMA. 2009;301:1439-50 JACC. 2012;60:1899-905

HF-ACTION Trial Criticisms of HF-ACTION Participants could not be enrolled until 6 weeks after hospitalization Safety of earlier enrollment to reduce readmission is unknown CPX and 6-minute walk as metrics to assess ET efficacy, safety, and stability Many see this as barrier to implementation Options to use exercise assessments more selectively to make ET more accessible and uncomplicated in relatively stable subsets of HF patients Few adults >75 years of age, limited exercise modalities, HFpEF, LVADs JAMA. 2009;301:1439-50 JACC. 2012;60:1899-905

Heart failure and exercise-based rehabilitation: Cochrane Review 2014 33 RCTs with 4740 participants Included both HF r EF and HF p EF, primarily NYHA classes II and III Exercise-based rehabilitation versus noexercise control At least 1-year follow-up Small body of evidence for HFpEF 3 trials Taylor RS, et al. Cochrane Database of Systematic Reviews. 2014;doi:10.1002/14651858.CD003331.pub4

Heart failure and exercise-based rehabilitation: Cochrane Review 2014 No difference in pooled mortality between exercise-based rehabilitation vs. no exercise control in trials with up to 1 year f/u RR 0.93, 05% CI 0.69 to 1.27 However, there was trend toward reduction in mortality in trials with >1 year f/u (RR 0.88, 95% CI 0.75 to 1.02) ET reduced rate of overall and HF specific hospitalizations RR 0.61, 95% CI 0.46 to 0.80 Significant improvement in in QOL measures Independent of age, gender, LF dysfunction, type of CR, dose of exercise, length of f/u Taylor RS, et al. Cochrane Database of Systematic Reviews. 2014;doi:10.1002/14651858.CD003331.pub4

Heart failure and exercise-based rehabilitation: Cochrane Review 2014 Conclusions ET does not increase or decrease risk of all-cause mortality in short-term (1-year) ET reduces the risk of hospital admissions ET confers important improvements in health-related quality of life May reduce mortality in the longer term Benefits consistent across participant characteristics Further RCT evidence needed for HFpEF Taylor RS, et al. Cochrane Database of Systematic Reviews. 2014;doi:10.1002/14651858.CD003331.pub4

Exercise in HFpEF HFpEF now approximately 54% of patients presenting with HF Dual effects of intrinsic age-related susceptibility to HFpEF and the expanding older adult population, as well as high prevalence of associated comorbidities (HTN, DM, afib, obesity) Severe exercise intolerance is the principal clinical feature in HFpEF (measured as decreased peak VO 2 ) Eur J Prev Cardiol. 2016;23:4-13

Exercise in HFpEF 2016 systematic review of RCTs comparing ET in patients with HFpEF 7 published studies 279 patients, 157 allocated to ET/122 allocated to control NYHA class I-III LVEF >45% Different exercise training modalities/protocols Eur J Prev Cardiol. 2016;23:4-13

Exercise in HFpEF Improvement in peak VO 2 Some showed improvement in QOL scores Variable effects on echocardiographic variables No consistent effect on BNP or surrogate endpoints (EC function, arterial stiffness) No studies designed to analyze CV outcomes No serious adverse events Findings contrast with robust information availab on ET for HFrEF patients (30 trials with >4000 patients) Eur J Prev Cardiol. 2016;23:4-13

Exercise in HFpEF Data limited by few trials, few patients Heterogeneous interventions Heterogeneous criteria for defining HFpEF Heterogeneous populations Varying endpoints Eur J Prev Cardiol. 2016;23:4-13

Exercise in older adults with HF National Institute on Aging REHAB-HF (Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients) Older adults with acute decompensated HFpEF and HFrEF (age >60 years, n=360) Randomized in a 1:1 fashion to 12-week novel, progressive, multi-domain rehabilitation and exercise training intervention or attention control Endurance, mobility, strength, and balance training 3 times per week in an outpatient setting Control arm will receive all services ordered by their primary physician and will be contacted bi-weekly by study staff. Measures of physical function and quality of life at baseline, 1 month, and 3 months. Clinical events monitored for 6 months following the index hospitalization. http://clinicaltrials.gov/ct2/show/nct02196038

Exercise in older adults with HF National Institute on Aging REHAB-HF (Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients) Primary outcome is improved physical function Secondary outcome is re-hospitalization Other assessments include frailty, multi-morbidity, polypharmacy, and other age-related complexities of care JACC. 2015;65:2652-59

Exercise in patients with LVADs: REHAB-VAD RCT Enrolled subjects n=26; 7 women; mean age 55 years; mean LVEF 21% Assessments: Symptom limited CPX, Kansas City Cardiomyopathy Questionnaire (KCCQ) 6-min walk test Single-leg isokinetic strength test 2:1 randomization to CR versus usual care CR group: 18 visits of aerobic exercise at 60% to 80% of heart rate reserve. JACC Heart Failure. 2014;2:653-9

Cardiac Rehabilitation Improves Functional Capacity and Patient-Reported Health Status in Patients With Continuous-Flow Left Ventricular Assist Devices : The Rehab-VAD Randomized Controlled Trial Peak VO2 for Subjects in Both the CR and Usual Care Groups Lines represent change over time for each patient. Darker lines indicate average change over time for both groups. JACC: Heart Failure, Volume 2, Issue 6, 2014, 653 659

Cardiac Rehabilitation Improves Functional Capacity and Patient-Reported Health Status in Patients With Continuous-Flow Left Ventricular Assist Devices : The Rehab-VAD Randomized Controlled Trial Kansas City Cardiomyopathy Questionnaire Summary Score for CR and Usual Care Group Subjects For CR group, changes at follow-up were significant (*p = 0.001) and significantly different from changes in the usual care group ( p = 0.005). Single Leg Isokinetic Strength Measures for CR and Usual Care Group Subjects The change at follow-up was significant in the CR group (*p = 0.003) and significantly different from changes in the usual care group ( p = 0.016). JACC: Heart Failure, Volume 2, Issue 6, 2014, 653 659

Exercise in patients with LVADs: REHAB-VAD RCT Improvements in CR group Peak oxygen uptake Treadmill time Kansas City Cardiomyopathy Questionnaire score 6 minute walk distance Leg strength Need future trials of outcomes JACC Heart Failure. 2014;2:653-9

Exercise in patients with LVADs Improved survival, functional capacity, health status Many patients still experience exercise intolerance and HF-related symptoms. Careful, structured, medically supervised exercise-based training is advocated. Address challenges that influence quality of life and independence As durability of LVADs improve and duration of support is extended, optimization of functional capacity and health status is critical.

Exercise in HF patients with CRT >50% patients with HF have implanted pacemaker or ICD Few longitudinal data on exercise and outcomes in patients with implanted cardiac rhythm devices Even less known about ET in patients with RV vs. BiV pacing Analysis of HF-ACTION trial in patients with pacemakers, ICDs, and BiV pacemakers (n=1118, 48%) 435 with BiV pacemakers or BiV ICDs J Cardiac Fail. 2015;21:60-67

Exercise in HF patients with CRT Patients with devices were older, more frequently white, and had lower peak VO 2. ET may improve exercise capacity in Peak VO 2 improved patients with similarly implanted with cardiac ET in devices, groups with and without pacing but beneficial devices. effects on hospitalization or death may be attenuated. Primary composite endpoint, all-cause death or hospitalization reduced only in patients randomized to ET without a device. HR 0.79, 95% CI 0.67 to 0.93; p=0.004 J Cardiac Fail. 2015;21:60-67

Exercise in HF patients with CRT 52 patients with CRT-D NYHA class III N=26 underwent ET in hospital and continued home program with telemonitoring 5 times per week N=26 had hospital rehab but no home training program CRT-EX group achieved better peak VO 2, peak and treadmill test duration at 3-4 months Benefits not sustained at 12- and 18-month f/u International J Cardiol. 2015;199:442-447

Exercise in HF patients with CRT Safe option for additional treatment Improved physical fitness Improved QOL measures Benefits not sustained No impact on mortality or hospitalization rates International J Cardiol. 2015;199:442-447

Guidelines for Management of HF ACCF/AHA 2013 ESC 2012 NICE 2010 All consistently recommend CR as an effective and safe intervention in HF.

Guidelines for Management of HF ACCF/AHA 2013 Class I Exercise training (or regular physical activity) is recommended as safe and effective for patients with HF who are able to participate to improve functional status. (Level of evidence: A) Circulation. 2013;128:e240-e327

Guidelines for Management of HF ACCF/AHA 2013 Class IIa Cardiac rehabilitation can be useful in clinically stable patients with HF to improve functional status, exercise duration, health-related quality of life, and mortality. (Level of evidence: B) Circulation. 2013;128:e240-e327

Guidelines for Management of HF ACCF/AHA 2013 Exercise training is safe and has numerous benefits. CR reduces mortality, improves functional capacity, exercise duration, and HRQOL. CR reduces hospitalizations. Improves EC function, blunts catecholamine spillover, and increases peripheral oxygen extraction. Circulation. 2013;128:e240-e327

Guidelines for Management of HF 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Exercise testing in patients with HF should be considered to optimize prescription of exercise training (preferably cardiopulmonary exercise testing). (IIa C) Combined endurance/resistance training appears safe for patients with HFpEF and HFmrEF and improves exercise capacity (as reflected by an increase in peak oxygen consumption), physical functioning score and diastolic function. Psychosocial intervention and pharmacological treatment are helpful, as well as exercise training, in patients with HFrEF and depression. European Heart Journal doi:10.1093/eurheartj/ehw128

Guidelines for Management of HF 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure European Heart Journal doi:10.1093/eurheartj/ehw128

2011 ESC Position Statement: Exercise training in heart failure Promotion of common daily activities (brisk walking, climbing stairs, housework, gardening, recreational pursuits) Structured physical activity/exercise training Appropriate patient selection (stable NYHA class I-III, early mobilization after acute exacerbation) Training protocol identification Exercise intensity Monitoring of progression

Exercise training in heart failure: from theory to practice. A consensus document of the HFA and the EACPR European Journal of Heart Failure. 2011;13:347-357

2011 ESC Position Statement: Exercise training in heart failure Specific populations Implantable cardioverter defibrillators Cardiac resynchronization therapy Limited literature Real-world experience shows ET can be performed safely

2011 ESC Position Statement: Exercise training in heart failure Recommend symptom-limited CPX Chronotropic response to exercise Exercise-induced arrhythmias Effectiveness of pharmacological heart rate control Risk of reaching HR in the ICD intervention zone Begin ET under medical supervision with monitoring

2011 ESC Position Statement: Exercise training in heart failure Staff caring for patients with ICD should be aware of: Underlying heart disease/etiology Reason for ICD implantation Triggers of arrhythmia (ischemia, specific HRs, etc.) Arrhythmia substrate ICD intervention HR zone Sequence of therapy (monitoring zone, anti-tachycardia pacing, and shock)

2010 NICE Guideline: Chronic heart failure management Rehabilitation Offer a supervised group exercise-based rehabilitation programme designed for patients with heart failure. Ensure the patient is stable and does not have a condition or device that would preclude an exercise-based rehabilitation programme. Include a psychological and educational component in the programme. The programme may be incorporated within an existing cardiac rehabilitation programme. nice.org.uk/guidance/cg108

2010 NICE Guideline: Chronic heart failure management Rehabilitation The conditions and devices that may preclude an exercisebased rehabilitation programme include: Uncontrolled ventricular response to atrial fibrillation Uncontrolled hypertension High-energy pacing devices set to be activated at rates likely to be achieved during exercise nice.org.uk/guidance/cg108

Heart Failure and CR: Challenges and Opportunities Strong rational for HFrEF Persistent underutilization of CR for patients with CHD would suggest the same is likely to be true for HF Shifts in US healthcare system seem likely to increase emphasis on CR February 2014 CMS decision to include HFrEF as eligible diagnosis for CR payment was import step, but only part of solution Additional insights needed regarding HFpEF, older adults, adherence, efficacy, financial feasibility, efficacy JACC. 2015;65:2652 2659

Heart Failure and CR: Challenges and Opportunities Central Illustration. Heart Failure and CR: Challenges and OpportunitiesCardiac rehabilitation (CR) provides proven benefits for heart failure with reduced ejection fraction patients, particularly functional gains, improved quality of life, and decreased hospi... JACC. 2015;65:2652 2659